Table 2 Demographics and clinical variables of the study population, including variations over time normalised for the time difference between CMR-0 and CMR-1 in months
N | 15 | |||
Age (years) | 25 (16–29) | |||
Males (%) | 9 (60) | |||
Follow-up (months) | 17 (12–23) | |||
CMR-0 | CMR-1 | Variation per month | pCMR-0−CMR-1 | |
LV EDVi (mL/m2) | 70 (61–72) | 81 (69–92) | 0 (0–1) | 0.025a |
LV ESVi (mL/m2) | 24 (21–28) | 32 (25–35) | 0 (0–1) | 0.050a |
LV SV (mL) | 67 (63–77) | 82 (68–92) | 1 (0–1) | 0.060 |
LV EF (%) | 64 (59–68) | 62 (59–65) | 0 (-1–0) | 0.240 |
RV EDVi (mL/m2) | 120 (100–128) | 94 (82–101) | -1 (-2–0) | 0.009a |
RV ESVi (mL/m2) | 53 (41–61) | 42 (34–48) | -1 (-1–0) | 0.048a |
RV SV (mL) | 124 (102–124) | 88 (66–92) | -2 (-2–-1) | 0.017a |
RV EF (%) | 53 (51–59) | 53 (50–60) | 0 (0–1) | 0.339 |
RV LGE (mL) | 4.49 (3.70–5.78) | − | ||
RV LGE (%) | 5.63 (4.92–7.00) | − | ||
RV LGE score | 7 (6–9) | − | ||